IL296881A - New antigens specific for acute myeloid leukemia (aml) and their uses - Google Patents

New antigens specific for acute myeloid leukemia (aml) and their uses

Info

Publication number
IL296881A
IL296881A IL296881A IL29688122A IL296881A IL 296881 A IL296881 A IL 296881A IL 296881 A IL296881 A IL 296881A IL 29688122 A IL29688122 A IL 29688122A IL 296881 A IL296881 A IL 296881A
Authority
IL
Israel
Prior art keywords
seq
hla
tap
leukemia
molecule
Prior art date
Application number
IL296881A
Other languages
English (en)
Hebrew (he)
Original Assignee
Universit? De Montr?Al
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universit? De Montr?Al filed Critical Universit? De Montr?Al
Publication of IL296881A publication Critical patent/IL296881A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL296881A 2020-04-14 2021-03-15 New antigens specific for acute myeloid leukemia (aml) and their uses IL296881A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009853P 2020-04-14 2020-04-14
PCT/CA2021/050340 WO2021207823A1 (en) 2020-04-14 2021-03-15 Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof

Publications (1)

Publication Number Publication Date
IL296881A true IL296881A (en) 2022-12-01

Family

ID=78083452

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296881A IL296881A (en) 2020-04-14 2021-03-15 New antigens specific for acute myeloid leukemia (aml) and their uses

Country Status (11)

Country Link
US (1) US20230287070A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136099A4 (cg-RX-API-DMAC7.html)
JP (2) JP7822953B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220167288A (cg-RX-API-DMAC7.html)
CN (1) CN115397842A (cg-RX-API-DMAC7.html)
AU (1) AU2021256477A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020376A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173666A1 (cg-RX-API-DMAC7.html)
IL (1) IL296881A (cg-RX-API-DMAC7.html)
MX (1) MX2022012758A (cg-RX-API-DMAC7.html)
WO (1) WO2021207823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114045341B (zh) * 2021-11-30 2024-03-01 中南大学 口腔黏膜下纤维化恶性进展或其所致口腔癌的早期诊断和/或预后生物标志物的应用及产品
WO2024077376A1 (en) * 2022-10-11 2024-04-18 Université de Montréal Novel tumor-specific antigens for myeloid leukemia and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
EP2576614A4 (en) * 2010-05-24 2013-11-13 Phosimmune Inc CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
SG11201507883SA (en) * 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr) * 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
HRP20200967T1 (hr) * 2014-06-20 2020-10-16 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP3277841A1 (en) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
WO2016209079A1 (en) * 2015-06-24 2016-12-29 Aimm Therapeutics B.V. Aml antigens and uses thereof
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CN109071605A (zh) * 2016-04-06 2018-12-21 伊玛提克斯生物技术有限公司 用于aml和其他癌症免疫治疗的新型肽和肽组合物
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EA201992416A1 (ru) * 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
CN112639136B (zh) * 2018-08-30 2024-08-02 蒙特利尔大学 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法
TW202024121A (zh) * 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法

Also Published As

Publication number Publication date
EP4136099A4 (en) 2024-08-07
CN115397842A (zh) 2022-11-25
CA3173666A1 (en) 2021-10-21
AU2021256477A1 (en) 2022-11-10
BR112022020376A2 (pt) 2022-11-22
JP2026009916A (ja) 2026-01-21
JP2023521219A (ja) 2023-05-23
US20230287070A1 (en) 2023-09-14
MX2022012758A (es) 2022-11-30
EP4136099A1 (en) 2023-02-22
JP7822953B2 (ja) 2026-03-03
WO2021207823A1 (en) 2021-10-21
KR20220167288A (ko) 2022-12-20

Similar Documents

Publication Publication Date Title
Ehx et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes
Ely et al. Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
US20230242583A1 (en) Proteogenomic-based method for identifying tumor-specific antigens
Apavaloaei et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
JP2026009916A (ja) 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
US20250136937A1 (en) Novel tumor-specific antigens for colorectal cancer and uses thereof
Gumpert et al. Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer
WO2025097243A1 (en) Colorectal tumor antigens and uses thereof
US20260048105A1 (en) Novel antigens for cancer and uses thereof
Wang et al. Pooled screening identifies combinatorial CAR signaling domains for next-generation CAR-M immunotherapies
US20240382590A1 (en) Novel tumor-specific antigens for cancer stem cells and uses thereof
Thelen Endogenous antigen-specific T and B cell immune responses in cancer and invasive infections are frequent, but often limited by potentially targetable immune escape mechanisms
Okada et al. Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens
Lahman Impact of Proteasomal Processing on Immunopeptidome Repertoires and Therapeutic Immune Recognition